The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome

BACKGROUND: Most patients with acute myeloid leukaemia are older, with many unsuitable for conventional chemotherapy. Low dose Ara-C (LDAC) is superior to best supportive care but is still inadequate. The combination of arsenic trioxide (ATO) and LDAC showed promise in an un-randomised study. We rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Burnett, Alan K, Hills, Robert K, Hunter, Ann, Milligan, Donald, Kell, Jonathan, Wheatley, Keith, Yin, John, McMullin, Mary-Frances, Cahalin, Paul, Craig, Jenny, Bowen, David, Russell, Nigel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485444/
https://www.ncbi.nlm.nih.gov/pubmed/21475252
http://dx.doi.org/10.1038/leu.2011.59

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485444/
https://www.ncbi.nlm.nih.gov/pubmed/21475252
http://dx.doi.org/10.1038/leu.2011.59

Ejemplares similares